- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07937501
A Study of IPG11406 Tablets in Participants With Lupus Nephritis
A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety, Efficacy, And Pharmacokinetics Of IPG11406 Tablets In Participants With Lupus Nephritis
Lupus Nephritis (LN) is one of the most serious and common complications of Systemic Lupus Erythematosus (SLE). It is a chronic inflammatory disease triggered by abnormal autoimmunity and the deposition of immune complexes in the kidneys. Approximately 40% to 60% of SLE patients develop lupus nephritis at the onset of the disease, and the cumulative rate of kidney involvement during the course of the disease can even reach 90%.
The goal of this Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety, Efficacy, And Pharmacokinetics Of IPG11406 Tablets In Participants With Lupus Nephritis trial is to evaluate the efficacy ,safety and tolerability of different doses of IPG11406 tablets combined with standard treatment compared to placebo combined with standard treatment in participants with active lupus nephritis.
A total of 4 groups were designed the 10mg IPG11406 tablet group, the 20mg IPG11406 tablet group, the 40mg IPG11406 tablet group,and the placebo group. The ratio among the groups was 1:1:1:1. Participants were randomly assigned to the above 4 dosage groups, with 48 participants planned for each group, totaling approximately 192 participants enrolled.
After randomization, participants will receive a 24-week double-blind treatment, twice daily (BID).They will take the assigned study drug (IPG11406 tablets at 40mg, 20mg, 10mg or placebo) orally.Throughout the 24-week core treatment period, all participants in all groups should continue to receive the standard treatment as prescribed by the protocol.
The primary efficacy endpoint of the renal response will be determined by changes in proteinuria and renal function. For the renal function assessment in the study visits, the glomerular filtration rate will be estimated using the CKD-EPI formula; proteinuria will be evaluated using the urine protein-to-creatinine ratio (based on the 24-hour urine collected).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Qiaofeng Qu, Master
- Número de teléfono: +8621 34782827
- Correo electrónico: qfqu@immunophage.com.cn
Ubicaciones de estudio
-
-
Jiangsu
-
Nanjing, Jiangsu, Porcelana, 210008
- Nanjing DrumTower Hospital
-
Contacto:
- Sun Lingyun Principal Investigator
- Número de teléfono: +86 13705186409
- Correo electrónico: lingyunsun2012@163.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age: 18 - 70 years old (inclusive of 18 and 70), gender not restricted.
- Participants must meet the SLICC (Systemic Lupus International Collaborating Clinics, SLICC) criteria and have been diagnosed with systemic lupus erythematosus before screening.
- The 24-hour urine total protein of the participants is ≥ 1g or the urine protein-to-creatinine ratio (UPCR) is ≥ 1g/g (based on the collected 24-hour urine sample).
- The estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI formula is > 45 ml/min/1.73 m^2.
- According to the 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria, there is active, biopsy-proven type III or IV lupus nephritis (with or without type V); if there is no biopsy result from the 6 months before the screening visit, a biopsy must be conducted during the screening period to determine if the participant meets this inclusion criteria.
- According to the researcher's opinion, the participant has active lupus nephritis and requires induction therapy with high-dose glucocorticoids combined with mycophenolate mofetil.
- The participant is willing to take oral mycophenolate mofetil (MMF) during the study period. If the participant has previously taken MMF, they can continue with the previous MMF treatment. If the participant has not taken MMF before, it can be initiated based on the baseline.
- For participants who are taking drugs that may affect renal function (such as antihypertensive drugs, lipid-lowering drugs), the dose must be stable for at least 4 weeks before randomization and during the study period.
- Female participants with reproductive potential (defined as not undergoing surgical sterilization or having been post-menopausal for less than 1 year) must undergo a blood pregnancy test during the screening visit and the result must be negative; female or male participants with reproductive potential must have no pregnancy plans for at least 30 days before the first administration and within 6 months after the study, voluntarily take effective contraceptive measures (see attachment), and have no sperm donation or egg donation plans.
- Participants voluntarily participate in the study, understand and sign the informed consent form, and comply with the requirements in the informed consent form.
Exclusion Criteria:
-
Participants who have previously been treated with the following medications and are expected to still be within the drug washout period when the study drug is administered:
a. Taltazyme: 2 months; b. Belimumab: 2 months; other biologic B-cell targeted therapies: 2 months; c. Within 2 months before screening or during screening, oral administration of any JAK inhibitor, Bruton's tyrosine kinase (BTK) inhibitor, or tyrosine kinase 2 (TYK2) inhibitor, including baricitinib, tofacitinib, upadacitinib, fingolimod, ibrutinib, or fenbetidine; d. Participants who have received CAR-T therapy cannot be enrolled. e. Within less than 9 months before screening or during screening, any anti-CD20 therapy (such as rituximab, ofatumumab, or oriximab), CD19 targeted therapy, if received between 9 and 12 months before screening, peripheral blood CD19⁺ B cell count must be ≥ 25 cells/μL.
-
Participants who received cyclophosphamide (CYC) induction therapy within 1 month before screening.
-
Participants who used any immunomodulatory drugs or herbal preparations with potential impact on liver and kidney function within 4 weeks before screening, including but not limited to Tripterygium glycosides tablets, drugs containing aristolochic acid (such as Dragon's Liver-Clearing Pills, Coronary Heart-Soothing Pills, etc.), and known hepatotoxicity-laden ingredients such as Notoginseng and Tongshiguaiwu.
-
Participants with interstitial fibrosis/tubular atrophy (IF/TA) or glomerular sclerosis exceeding 50% in renal tissue biopsy.
-
Participants with rapidly progressive glomerulonephritis, as defined by any of the following:
- Renal biopsy assessment shows that ≥ 50% of glomeruli have crescent formation
- Serum creatinine has continuously doubled within 2 months before screening
- The investigator believes that the participant has rapidly progressive glomerulonephritis
-
Primary glomerular diseases or secondary nephropathy caused by systemic lupus erythematosus, including diabetic nephropathy, hypertensive renal damage, anti-glomerular basement membrane disease, viral hepatitis-related nephropathy, HIV-related nephropathy, purpura nephritis, paraproteinemia-related nephropathy, drug or toxin-related nephropathy, etc., which the investigator believes may interfere with LN assessment and will interfere with the assessment results of disease activity.
-
Participants at the time of screening visit still have ≥ 2 grade adverse events related to previous drug treatment (see the main text of the protocol - adverse event grading), or adverse events that affect the participant's inclusion/exclusion criteria judgment and/or participant's efficacy/safety assessment.
-
Participants who previously had or currently have severe neuropsychiatric SLE, including but not limited to the following: seizure, new or worsening impairment of consciousness, psychosis, delirium or confusion state, sterile meningitis, ascending or transverse myelitis, chorea, cerebellar ataxia, multiple mononeuritis, demyelinating syndrome or situations that prevent the participant from fully understanding ICF.
-
Any overlapping autoimmune diseases whose condition or treatment may affect the assessment or outcome of this study (such as scleroderma with significant pulmonary hypertension; any disease that requires additional immunosuppressive treatment), must be excluded. If the condition or treatment of overlapping diseases is expected not to affect the assessment or outcome of the study (such as Sjogren's syndrome), it is not excluded. Participants.
-
Participants who have had malignant tumors within the past 5 years.
-
Participants with active antiphospholipid antibody syndrome (APS) or requiring therapeutic anticoagulation.
-
Participants currently requiring renal dialysis (hemodialysis or peritoneal dialysis), or expected to require renal dialysis during the study.
-
Participants with a history of major organ transplantation (such as heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplantation.
-
Participants who have undergone major surgical procedures (craniotomy, thoracotomy or laparotomy) within the previous 4 weeks or have unhealed wounds, ulcers or fractures.
-
Participants who have received live/dead attenuated vaccinations or plan to receive live/dead attenuated vaccinations during the trial.
-
Participants with any of the following cardiac impairments: a. New York Heart Association functional classification grade III to IV; b. Uncontrolled angina pectoris, congestive heart failure or myocardial infarction within 6 months before the first dose administration; c. QTcF interval prolonged by Fridericia formula (male > 450 milliseconds; female > 470 milliseconds); d. Second-degree type II atrioventricular (AV) block, third-degree AV block or PR interval > 250 milliseconds, etc.; e. Various factors that may increase the risk of QTcF prolongation or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, and first-degree relatives in the family history had sudden death before the age of 40; f. Left ventricular ejection fraction (LVEF) < 50%.
-
Participants who are receiving treatment for chronic or recurrent infections, such as tuberculosis, pneumocystis pneumonia, herpes simplex virus and varicella-zoster virus.
-
Participants with positive HBsAg in the five-antibody test for hepatitis B (those with negative HBsAg but positive HBcAb need to do HBV-DNA quantitative test; those with HBV-DNA test result ≥ upper limit of reference value of each center or those requiring antiviral treatment do not meet the conditions for participating in the study); positive hepatitis C antibody (add HCV-RNA test if negative; those who are negative can be enrolled); positive Treponema pallidum antibody (if Treponema pallidum antibody is positive, further Treponema pallidum serological test is conducted; participants judged by the investigator as having had a past infection with syphilis but having been cured meet the inclusion criteria); positive HIV antibody test.
-
Participants with significantly abnormal liver, kidney function and blood routine test results, including: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) exceeding 2 times the upper limit of normal value, serum total bilirubin exceeding 1.5 times the upper limit of normal value; hemoglobin < 90 g/L; white blood cell count < 3.0×10^9/L, platelet count (PLT) < 75×10^9/L; neutrophil count < 1.0×10^9/L; and other abnormal laboratory test results, as determined by the investigator, may affect the participant's ability to complete the entire clinical research process or interfere with the safety/efficacy results of the study.
-
Participants have any condition that may prevent them from safely completing all clinical research procedures, such as being allergic to the test drug (including excipients), having a severe allergic disease or being of an allergic constitution, having a known difficulty in swallowing, experiencing anemias or needle phobia, being intolerant to oral or intravenous glucocorticoids or having contraindications, or being intolerant to mycophenolate mofetil.
-
Participants have any of the following major infection events:
- Hospitalized within the previous 8 weeks or during the screening period
- Received intravenous antibiotics or anti-infective drugs during the screening period
- Received oral antibiotics or anti-infective drugs within the previous 2 weeks or during the screening period
-
Note: If only using antibiotics or anti-infective drugs without major infection events does not constitute an exclusion criterion.
-
Participants have a history of drug abuse or drug misuse.
-
Pregnant or lactating female participants.
-
Participants who have participated in other clinical studies within 180 days before the screening, or who plan to participate in other clinical studies before the completion of all planned visits of this clinical study;
-
Other situations judged by the investigator as not suitable for inclusion.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: el grupo placebo
|
Twice daily, oral administration for 24 weeks. |
|
Experimental: 10mg IPG11406 tablet group
|
Twice daily, oral administration for 24 weeks. Twice daily, oral administration for 24 weeks. |
|
Experimental: 20mg IPG11406 tablet group
|
Twice daily, oral administration for 24 weeks. Twice daily, oral administration for 24 weeks. |
|
Experimental: 40mg IPG11406 tablet group
|
Twice daily, oral administration for 24 weeks. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The proportion of participants who achieved complete renal remission (Completerenalresponse, CRR) at the 24th week.
Periodo de tiempo: From enrollment to the end of treatment at 24 weeks
|
The definition of CRR is as follows:
|
From enrollment to the end of treatment at 24 weeks
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades del tejido conectivo
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Glomerulonefritis
- Lupus Eritematoso Sistémico
- Nefritis
- Enfermedades de la piel y del tejido conectivo
- Nefritis lúpica
Otros números de identificación del estudio
- IPG11406-C004
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .